- $67.90m
- -$49.31m
- $0.80m
Ikena Oncology Inc reports results for the quarter ended in December - Earnings Summary
U.S. RESEARCH ROUNDUP-Freeport-Mcmoran, Harley-Davidson, Varonis Systems
Brief: Ikena Oncology Reports Fourth Quarter And Full Year 2022 Financial Results
Ikena Oncology Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Ikena Oncology Presents Preclinical Data On Ik-595, Best-In-Class Next-Generation Mek-Raf Complex Inhibitor, In Plenary Session At AACR Special Conference On Ras Targeting
Brief: Ikena Oncology Receives FDA Fast Track Designation For Novel AHR Antagonist Ik-175 In Combination With Nivolumab To Treat Urothelial Carcinoma
Brief: Ikena Oncology Appoints Owen Hughes As Board Chair
U.S. RESEARCH ROUNDUP-Amazon.com, BorgWarner, Cincor pharma
Ikena Oncology Inc reports results for the quarter ended in September - Earnings Summary
Brief: Ikena Oncology Reports Third Quarter Results
Ikena Oncology Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Ikena Oncology Presents Preclinical Data At The 34Th Eortc-Nci-Aacr Symposium On Novel Tead Inhibitor, Ik-930, Combating Therapeutic Resistance
Sonendo up on launching platform to treat tooth decay
Brief: Ikena Oncology Posts Qtrly Loss Per Share $0.57
Ikena Oncology Inc reports results for the quarter ended in June - Earnings Summary
Ikena Oncology Inc expected to post a loss of 49 cents a share - Earnings Preview
Ikena Oncology Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ikena Oncology Reports First Quarter 2022 Financial Results
Ikena Oncology Inc expected to post a loss of 42 cents a share - Earnings Preview